There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Thanks to the tireless efforts of people like San Luis Obispo resident Frank Kalman and his nonprofit, End Kids Cancer, there have been major advances in pediatric oncology in recent years. Here's Kal ...

Crown BioScience experts explore organoid models and high-content imaging to evaluate T-cell-targeted therapies and ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous ...

The research team developed a special type of engineered EVs, called antigen-presenting extracellular vesicles (AP-EVs), that ...

Immune checkpoint inhibitors ... of lung cancer cells. They demonstrated that suppressing DDX54 enhances immune cell ...

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed ...

AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...

A number of recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia (CLL).

Tharimmune (THAR) announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to ...

CTLA4 Inhibitors Market forecast to 2035 covers market size, key trends, competitive landscape, and growth opportunities in cancer immunotherapy and autoimmune diseases.

Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...